Cargando…
Current therapy in children and adolescents with von Willebrand disease
Abstract The article represents a review of recent data about the therapy of von Willebrand disease in children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events in these patients, the indications in different subtypes, and the future lines of re...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197504/ https://www.ncbi.nlm.nih.gov/pubmed/25408737 |
_version_ | 1782339638434725888 |
---|---|
author | Buga-Corbu, I Arion, C |
author_facet | Buga-Corbu, I Arion, C |
author_sort | Buga-Corbu, I |
collection | PubMed |
description | Abstract The article represents a review of recent data about the therapy of von Willebrand disease in children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events in these patients, the indications in different subtypes, and the future lines of research are mentioned. Abbreviations: Ag VWF = von Willebrand antigen, VWD = von Willebrand disease, DDAVP = arginine-vasopressin, EACA = epsilon aminocaproic acid, VWF = von Willebrand factor, VIIc F = the VIIth factor of coagulation, VIIIc F = the VIIIth factor of coagulation, IgG = immunoglobulin G, T/2 = half-time, WVF – Rco = the ristocetin cofactor. |
format | Online Article Text |
id | pubmed-4197504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41975042014-11-18 Current therapy in children and adolescents with von Willebrand disease Buga-Corbu, I Arion, C J Med Life Case Presentation Abstract The article represents a review of recent data about the therapy of von Willebrand disease in children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events in these patients, the indications in different subtypes, and the future lines of research are mentioned. Abbreviations: Ag VWF = von Willebrand antigen, VWD = von Willebrand disease, DDAVP = arginine-vasopressin, EACA = epsilon aminocaproic acid, VWF = von Willebrand factor, VIIc F = the VIIth factor of coagulation, VIIIc F = the VIIIth factor of coagulation, IgG = immunoglobulin G, T/2 = half-time, WVF – Rco = the ristocetin cofactor. Carol Davila University Press 2014-06-15 2014-06-25 /pmc/articles/PMC4197504/ /pubmed/25408737 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Presentation Buga-Corbu, I Arion, C Current therapy in children and adolescents with von Willebrand disease |
title | Current therapy in children and adolescents with von Willebrand disease |
title_full | Current therapy in children and adolescents with von Willebrand disease |
title_fullStr | Current therapy in children and adolescents with von Willebrand disease |
title_full_unstemmed | Current therapy in children and adolescents with von Willebrand disease |
title_short | Current therapy in children and adolescents with von Willebrand disease |
title_sort | current therapy in children and adolescents with von willebrand disease |
topic | Case Presentation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197504/ https://www.ncbi.nlm.nih.gov/pubmed/25408737 |
work_keys_str_mv | AT bugacorbui currenttherapyinchildrenandadolescentswithvonwillebranddisease AT arionc currenttherapyinchildrenandadolescentswithvonwillebranddisease |